Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: A phase II open-label study

BioDrugs

Volumn 16, Issue 2, 2002, Pages 105-109

  Sulkowski, Mark ^a   Reindollar, Robert ^b   Thomas, David L ^a   Brinkley Laughton, Sherilyn ^a   Hudson, Martha ^b   Yu, Jian ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Carolinas Center for Liver Disease   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MACROGOL; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0036091231     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216020-00004     Document Type: Article

References (19)

1. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
2. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
3. Therapy of hepatitis C: Interferon alfa-n1 trials
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
6. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection
7. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects
8. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG[40kDa] IFN α-a) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
9. Efficacy of pegylated (40kDa) interferon alfa-2α (PEGASYS®) in randomized trials of patients with chronic hepatitis C, with and without cirrhosis: Correlation of virological and histological responses with baseline liver histology and genotype
10. Efficacy and safety of pegylated (40kDa) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C
11. Peginterferon α-2a in patients with chronic hepatitis C and cirrhosis
12. Induction regimen of interferon α-2a in patients with chronic hepatitis C
13. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
14. New perspectives in the diagnosis of hepatitis C
15. The effect of interferon alfa and ribavirin combination therapy in naïve patients with chronic hepatitis C
16. Interferon-α-2a: A review of its pharmacological properties and therapeutic use in the management of viral hepatitis
17. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
18. Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study